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Abstract
Breast cancer stem cells (BCSCs) are thought to be responsible for tumor initiation, metastasis and relapse. Our
group and others have described markers useful in isolating BCSCs just as aldehyde dehydrogenase positive (ALDH
+) or CD24−CD44+. In fact, cells which simultaneously express both sets of markers have the highest tumor initiating
capacity. Although the transcriptomic profile of cells expressing each BCSC marker alone has been reported, the
profile of the most tumorigenic population expressing both sets of markers has not. Here we used the biomarker
combination of ALDH and CD24/CD44 to sort four populations isolated from triple-negative breast cancer (TNBC)
patient-derived xenografts, and performed whole-transcriptome sequencing on each population. We systematically
compared the profiles of the three states of BCSCs (ALDH+CD24−CD44+, ALDH+non-CD24−CD44+ and ALDH−CD24
−CD44+) to that of the differentiated tumor cells (ALDH−non-CD24−CD44+). For the first time, we compared the
ALDH+CD24−CD44+ BCSCs with the other two BCSC populations. In ALDH+CD24−CD44+ BCSCs, we identified
P4HA2, PTGR1 and RAB40B as potential prognostic markers, which were virtually related to the status of BCSCs and
tumor growth in TNBC cells.
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Background
Triple-negative breast cancer (TNBC) is primarily identified
through a lack of expression of estrogen and progesterone
(ER and PR, respectively), and the gene ERBB2 (ER−PR
−HER2−) [1]. TNBC is the subtype of breast cancer with
the poorest clinical outcome and lack of targeted therapy
[2]. Cancer stem cells (CSCs) [3], or tumor-initiating cells,
are capable of self-renewal and differentiation, which are
considered to be responsible for tumorigenesis and cancer
relapse [4]. Eradication of breast cancer stem cells (BCSCs)
may result in improved clinical outcomes.
It is common to use fluorescent activated cell sorting
and specific biomarkers of BCSCs to isolate BCSCs from
heterogeneous tumor tissues, patient-derived xenografts
(PDXs) and cell lines [5–7]. BCSCs were widely recog-
nized to be enriched with the biomarkers CD24−CD44+
[8] or ALDH+ [9]. Our previous studies have demon-
strated cells expressing the biomarkers CD24−CD44+ and
ALDH+ exist across all subtypes of breast cancer, although
in varying proportions. Furthermore, we have demon-
strated that BCSCs in the mesenchymal state are charac-
terized as CD24−CD44+ BCSCs, while ALDH+ BCSCs are
characterized as epithelial [7]. In breast cancer, ALDH
+CD24−CD44+ cells are rare population within tumors
and cell lines, which are endowed with greatest tumori-
genesis and invasive capacity. ALDH+CD24−CD44+ cells
can generate tumors in NOD/SCID mice, showing the
greatest tumor-initiating capacity [9]. We postulate here
that the ALDH+CD24−CD44+ cells are more purified
BCSC population. Here we used the biomarker combina-
tions ALDH and CD24/CD44 to divide cells from two
TNBC PDXs into four groups to systematically compared
different states of BCSCs on transcriptome to get potential
prognostic genes in TNBC.
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Findings
Transcriptional analysis between three states of BCSCs and
the differentiated tumor cell population
To systematically characterize the transcriptional profiles
of BCSCs, we isolated four cell groups from two TNBC
PDXs, and performed whole-transcriptome sequencing
to identify differentially expressed genes (DEGs) between
four groups (Fig. 1a): (1) group A (ALDH+CD24−CD44+,
highly purified BCSCs); (2) group B (ALDH+non-CD24
−CD44+, enriched epithelial-like BCSCs); (3) group C
Fig. 1 Isolation and characterization of the four cell populations from PDXs. (a) The flow charts of ALDH, CD24 and CD44 for PDX1 and PDX2 by
fluorescent activated cell sorting. We isolated four groups based on biomarker combinations of ALDH and CD24/CD44. (b) The limiting dilutions of
cells obtained from PDX2 (VARI068) were implanted in the fourth fat pads of NOD-SCID mice. The tumor growth for each group was monitored and
calculated weekly, and the CSC frequency for the group A, B, C, D was calculated based on the website http://bioinf.wehi.edu.au/software/elda/. (c)
The expression of BCSC biomarkers ALDH, CD24 and CD44 in each sorted group. We compared each group with the following criteria: 1) CD24: A
< B, C < D; 2) CD44: A > B, C > D; 3) ALDH: A/B > C/D. PDXs have different expressions of ALDH isoforms. P1: PDX1; P2: PDX2
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(ALDH−CD24−CD44+, enriched mesenchymal-like
BCSCs); and (4) group D (ALDH−non-CD24−CD44+,
differentiated tumor cells). The tumorigenicity of each
cell population was analyzed in vivo, and the result dem-
onstrated that groups A and B had significantly higher
tumor-initiating capacity and CSC frequency than
groups C and D (Fig. 1b), with the highest tumorigen-
icity for group A. Moreover, the size of tumors in group
A was significantly larger than that in group B. The tran-
scriptomic data is shown in Additional file 1: Table S1.
The expression of BCSC biomarkers ALDH and CD24/
CD44 were as expected [7]: CD24: A < B, C < D; CD44:
A > B, C > D; ALDH: A/B > C/D (Fig. 1c). We systematic-
ally performed pair-comparisons between three subsets
of BCSCs and differentiated tumor cells (Additional file
1: Figure S1) with fold change set at 1.2 based on the
standard of our previous study [7]. The DEGs in A/D, B/
D and C/D pair-comparisons were 3223, 3387 and 3065,
respectively (Additional file 1: Figure S1a). For all states
of BCSCs in common, there were 391 DEGs in the inter-
section set (Additional file 1: Figure S1b). The Gene
Ontology (GO) analysis based on biological process indi-
cated that the 391 DEGs involved in cellular response to
hypoxia, cell adhesion, extracellular matrix organization,
cell cycle, etc. (Additional file 2: Table S2). To characterize
the exclusively transcriptional features of each state of
BCSCs, we overlapped the DEGs of three pair-comparisons
(Additional file 1: Figure S1b), and found that each state
has its own unique DEGs (Additional file 1: Figure S1b), of
which the altered GO terms were different identified by
DAVID 6.8 and Gene Set Enrichment Analysis (GSEA)
(Additional file 1: Figure S2, Additional file 3: Table S3),
suggesting that three populations of the ALDH+CD24
−CD44+, the ALDH+non-CD24−CD44+ and the ALDH
−CD24−CD44+ were different states of BCSCs. In addition,
we also found that the epithelial markers, CDH3, CLDN3,
CLDN4, CLDN7 and MKI67, were highly expressed in the
ALDH+non-CD24−CD44− BCSCs, while the mesenchymal
markers, CDH2, FOXC2, MMP2, SNAI2 and TWIST1,
were highly expressed in the ALDH−CD24−CD44+ BCSCs
(Additional file 1: Figure S3).
Comparison of the gene transcription between ALDH+CD24
−CD44+ BCSCs and the other three groups
To identify the DEGs in ALDH+CD24−CD44+ BCSCs,
we compared group A with the other three groups with
fold change set at 1.2 in analyzed PDXs (Fig. 2a). The
numbers of intersected A/X (X stands for groups B, C or
D) DEGs overlapped in analyzed PDXs were 3505 and
2360, respectively (Fig. 2a). We performed principal
component analysis to further distinguish group A from
the other three groups in each PDX, trimming DEGs to
3105 and 1851 for PDX1 and PDX2, respectively (Fig. 2b,
c). Then we overlapped the trimmed DEGs of analyzed
PDXs and identified 513 DEGs in the intersection set
(Fig.2c, d). After analyzing the 513 DEGs by GO analysis
and KEGG pathway analysis, we found that ALDH+CD24
−CD44+ BCSCs differed from the other populations in p53
signaling pathway, signaling pathways regulating pluripo-
tency of stem cells, and central carbon metabolism in can-
cer, etc. (Fig. 2e, f, Additional file 4: Table S4). GSEA of
the 513 DEGs also showed that the process of differenti-
ation and development in ALDH+CD24−CD44+ BCSCs
was significantly downregulated (Additional file 1: Figure
S2, Additional file 3: Table S3).
Identification of the potential prognostic genes enriched in
ALDH+CD24−CD44+ BCSCs of TNBC
To obtain unique A/X DEGs (X stands for groups B, C
or D), we identified 90 out of 513 DEGs in two PDXs,
the 38 upregulated (A > X) and 52 downregulated (A <
X) genes in common (Additional file 1: Figure S4a). The
GO analysis based on biological process identified
PPIL3, P4HA2 and FKBP2 from 38 upregulated genes
were involved in peptidyl-proline modification, suggest-
ing that there might be some epigenetic modifications
exclusively in BCSCs, while 52 downregulated genes
were involved in regulation of cell differentiation, posi-
tive regulation of developmental process, regulation of
multicellular organismal development and regulation of
cell development (Additional file 4: Table S4). To search
for potential prognostic markers of TNBC, we used the
Kaplan-Meier plotter [10] to screen the 90 DEGs identi-
fied from ALDH+CD24−CD44+ BCSCs in analyzed
PDXs. Among the 90 DEGs of purified BCSCs in PDXs
(Additional file 1: Figure S4a), the high expression of
P4HA2 (n = 255, p = 0.00057) and PTGR1 (n = 161, p =
0.001), and low expression of RAB40B (n = 255, p =
0.0069) in TNBC patients were associated with de-
creased RFS (Additional file 1: Figure S4b).
Knockdown of potential prognostic genes affected the
status of BCSCs
As assessed by quantitative real-time PCR (qRT-PCR),
the relative expressions of PTGR1, P4HA2 and RAB40B
was variable across different breast cancer cell lines, for
instance, the expression of RAB40B was comparatively
lower in TNBC cell lines, such as SUM149, SUM159 and
MDAMB231, than those of the other cell lines (Fig. 3a).
To further elucidate the role of these genes in TNBC, we
used shRNA to knock down each gene in TNBC cell line
SUM149. The expressions of PTGR1, P4HA2 and RAB40B
were significantly lower after lentivirus infection con-
firmed by qRT-PCR (Fig. 3b). Knockdown of P4HA2 or
PTGR1 downregulated CSC-related genes, such as SOX2,
OCT4 and NANOG (Fig. 3b), as well as causing a signifi-
cant decrease in the proportion of BCSCs as assessed by
ALDEFLUOR assay (Fig. 3c) and mammosphere
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formation assay (Fig. 3d). However, knockdown of P4HA2
or PTGR1 had no effect on CD24−CD44+ population of
SUM149, but only on ALDH+ population (Fig. 3c). In
addition to their effect on the BCSC population, knock-
down of P4HA2 or PTGR1 also inhibited cell proliferation
verified by MTT assay (Fig. 3e). When we knocked down
RAB40B, the CSC-related genes, SOX2 and OCT4, were
upregulated (Fig. 3b). In addition to that, the amount of
the mesenchymal-like BCSCs (CD24−CD44+) was in-
creased (Fig. 3c). Interestingly, knockdown of RAB40B
also prevented mammosphere formation (Fig. 3d) and cell
proliferation in SUM149 (Fig. 3e). To further validate the
function of RAB40B in TNBC, we used two different
shRNAs (RAB40BSh-sh2 used in SUM149, and another
new sequence RAN40BSh-sh3) to knockdown the expression
of RAB40B in another two TNBC cell lines: SUM159 and
MDA-MB-231. The shRNAs worked well as assessed by
qRT-PCR (Additional file 1: Figure S5a). Knockdown of
RAB40B up-regulated CSC-related genes, such as SOX2,
OCT4 and NANOG (Additional file 1: Figure S5.a), consist-
ent with the results in SUM149 (Fig. 3b). Knockdown of
RAB40B had no effect on CD24−CD44+ population of
Fig. 2 The unique DEGs of ALDH+CD24−CD44+ BCSCs. (a) The Venn diagrams of the DEGs between ALDH+CD24−CD44+ BCSCs (group A) and
other three groups with fold change set 1.2. (b) The principal component analysis (PCA) plots of DEGs in two PDXs. (c) The intersection set of
DEGs after filtered by PCA in two PDXs. (d) The intersected 513 DEGs in two PDXs. (e) The GO analysis based on biological processes of the 513
DEGs visualized by Apps ClueGO v2.3.2 of Cytoscape v3.4.0 with network specificity set Global. (f) The KEGG pathway analysis of the 513 DEGs
visualized by Cytoscape v3.4.0 with network specificity set medium
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SUM159 and MDA-MB-231 (Additional file 1: Figure S5b),
however, knockdown of RAB40B significantly increased
ALDH+ population (Additional file 1: Figure S5b), as well as
causing a remarkable increase in mammosphere forma-
tion (Additional file 1: Figure S5c) and proliferation
(Additional file 1: Figure S5d). These results seemed
contradictory with the observation from SUM149, but
this observation suggested RAB40B might play different
roles in different cancer cells by affecting different
BCSC population and also supported our previous re-
port about the different proliferative capacity and cellu-
lar function between ALDH+ population and CD24
−CD44+ population [7]. The functional analysis demon-
strated that knockdown of the three potential
Fig. 3 Functional analysis of potential prognostic genes. (a) The expressions of PTGR1, P4HA2 and RAB40B was variable across different breast cell lines,
including: 1) normal mammary gland cell lines, MCF10A and HBL100; 2) luminal breast cancer cell lines, MCF7 and T47D (ER+PR−HER2−); 3) HER2+
breast cancer cell lines (ER−PR−HER2+) containing SKBR3, BT474; 4) Basal-like/TNBC (ER−PR−HER2−) breast cancer cell lines, such as MDA-MB-468,
HCC1937, SUM149, SUM159 and MDA-MB-231. (b) The expressions of CSC-related genes (ShPTGR1, ShP4HA2 and ShRAB40B) in the knockdown and
the control (Shctrl) TNBC cell line SUM149. (c) The fold change for the proportion of each BCSC state in knockdown cells vs. Shctrl cells as assessed by
fluorescent activated cell sorting. (d) The mammosphere formed in Shctrl cells and knockdown cells accessed by mammosphere formation assay. (e)
The fold change for cell proliferation of knockdown SUM149 cells vs. Shctrl SUM149 cells as assessed by MTT assay . *, P < 0.05; **, P < 0.01; ***, P <
0.001; ns, not significant (compared with the corresponding Shctrl group). Error bars, mean ± SD
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prognostic markers would significantly affect the status
of BCSCs and tumor growth simultaneously, indicating
these genes might serve as the important prognostic
markers in TNBC.
Conclusion
This is the first transcriptional characterization of the
ALDH+CD24−CD44+ BCSCs in TNBC, as well as the first
comparisons between the ALDH+CD24−CD44+ BCSCs
and other types of BCSCs in TNBC. In ALDH+CD24
−CD44+ BCSCs, we identified three potential prognostic
markers, P4HA2, PTGR1 and RAB40B, which were related
to the status of BCSCs and tumor growth in TNBC cells.
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